[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fhQzZPIgjc5F8pbKSxXqf7BnVjHqZZtmd3z47dTtzxxw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":40,"rows":47},"Endo Pharmaceuticals",[4],105,false,1,48,26556,8,[13,16,18,21,24,27,30,32],{"name":14,"count":15},"Cellulite",11,{"name":17,"count":15},"Edematous Fibrosclerotic Panniculopathy",{"name":19,"count":20},"Peyronie's Disease",9,{"name":22,"count":23},"Dupuytren's Contracture",7,{"name":25,"count":26},"Chronic Pain",6,{"name":28,"count":29},"Adhesive Capsulitis",4,{"name":31,"count":29},"Frozen Shoulder",{"name":33,"count":29},"Edematous Fibrosclerotic Panniculopathy (EFP)",[35],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06151197","Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)","2026-03","EN3835",[41,42,43,44,45,46],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[48,138,296,362,419,469,516,551,573,604,622,640,658,676,694,712,741,759,777,795,813,896,951,997,1038,1073,1111,1137,1155,1177,1202,1226,1252,1279,1297,1320,1344,1367,1390,1408,1434,1459,1483,1506,1528,1553,1577,1600,1618,1641,1659,1683,1709,1727,1752,1770,1788,1806,1834,1852,1877,1903,1925,1948,1979,2003,2026],{"intervention":39,"totalTrials":11,"cells":49},{"EARLY_PHASE1":50,"PHASE1":53,"PHASE2":55,"PHASE3":87,"PHASE4":134,"NA":136},{"trials":51,"activeCount":52},[],0,{"trials":54,"activeCount":52},[],{"trials":56,"activeCount":52},[57,67,77],{"nctId":58,"briefTitle":59,"status":60,"phases":61,"primaryCompletion":62,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":66},"NCT04496167","Safety and Efficacy of EN3835 in Participants With Frozen Shoulder","COMPLETED",[43],"2022-04-14","2020-07-29",198,[28,31],[39],{"nctId":68,"briefTitle":69,"status":70,"phases":71,"primaryCompletion":72,"completion":73,"start":74,"enrollment":23,"conditions":75,"interventions":76},"NCT04209530","Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women","TERMINATED",[43],"2020-07-23","2020-10-05","2019-11-20",[14,33],[39],{"nctId":78,"briefTitle":79,"status":60,"phases":80,"primaryCompletion":81,"completion":81,"start":82,"enrollment":83,"conditions":84,"interventions":86},"NCT05152173","Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis",[43],"2023-01-10","2021-11-29",176,[85],"Plantar Fibromatosis",[39],{"trials":88,"activeCount":8,"soonestReadout":38},[89,99,107,116,124],{"nctId":90,"briefTitle":91,"status":60,"phases":92,"primaryCompletion":93,"completion":93,"start":94,"enrollment":95,"conditions":96,"interventions":98},"NCT03446781","Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women",[44],"2018-09-26","2018-02-08",422,[97],"Edematous Fibrosclerotic Panniculopathy (Cellulite)",[39],{"nctId":36,"briefTitle":37,"status":100,"phases":101,"primaryCompletion":38,"completion":38,"start":102,"enrollment":103,"conditions":104,"interventions":106},"ACTIVE_NOT_RECRUITING",[44],"2023-11-28",418,[85,105],"Ledderhose Disease",[39],{"nctId":108,"briefTitle":109,"status":60,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"NCT05254457","Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis",[44],"2024-03-21","2022-02-14",145,[85],[39],{"nctId":117,"briefTitle":118,"status":60,"phases":119,"primaryCompletion":93,"completion":93,"start":120,"enrollment":121,"conditions":122,"interventions":123},"NCT03428750","Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women",[44],"2018-02-05",423,[97],[39],{"nctId":125,"briefTitle":126,"status":60,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":133},"NCT04170296","Real World CCH Study in Adult Females With Cellulite",[44],"2020-10-06","2021-01-08","2019-11-01",153,[33,14],[39],{"trials":135,"activeCount":52},[],{"trials":137,"activeCount":52},[],{"intervention":139,"totalTrials":140,"cells":141},"collagenase clostridium histolyticum",15,{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":167,"PHASE3":255,"PHASE4":284,"NA":294},{"trials":143,"activeCount":52},[],{"trials":145,"activeCount":52},[146,156],{"nctId":147,"briefTitle":148,"status":60,"phases":149,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":155},"NCT00528931","A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture",[42],"2007-12","2008-03","2007-09",16,[22],[139],{"nctId":157,"briefTitle":158,"status":60,"phases":159,"primaryCompletion":160,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},"NCT01518907","The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)",[42],"2012-12","2013-02","2012-01",99,[17,14],[166],"COLLAGENASE CLOSTRIDIUM HISTOLYTICUM",{"trials":168,"activeCount":52},[169,179,188,198,208,217,227,236,247],{"nctId":170,"briefTitle":171,"status":60,"phases":172,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":177},"NCT02006719","Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder",[43],"2014-12","2013-11",322,[28,31],[178],"Collagenase Clostridium Histolyticum",{"nctId":180,"briefTitle":181,"status":60,"phases":182,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":187},"NCT02942160","EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)",[43],"2018-06-14","2016-10-05",259,[17,14],[178],{"nctId":189,"briefTitle":190,"status":60,"phases":191,"primaryCompletion":173,"completion":173,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT02193828","Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules",[43],"2014-07",76,[195],"Dupuytren's Disease",[197],"Collagenase clostridium histolyticum",{"nctId":199,"briefTitle":200,"status":60,"phases":201,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},"NCT06169319","A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)",[43],"2024-09-30","2024-01-03",231,[206],"Plantar Fasciitis",[178],{"nctId":209,"briefTitle":210,"status":60,"phases":211,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":216},"NCT01987986","A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy",[43],"2014-08","2013-10",150,[33],[178],{"nctId":218,"briefTitle":219,"status":60,"phases":220,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":226},"NCT03632993","Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)",[43],"2019-01-24","2018-09-18",64,[225],"Edematous Skin",[139],{"nctId":228,"briefTitle":229,"status":60,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":235},"NCT03329989","Safety and Effectiveness of EN3835 in the Treatment of EFP in Women",[43],"2018-09-05","2017-11-17",158,[17,14],[178],{"nctId":237,"briefTitle":238,"status":60,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":246},"NCT04580303","CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques",[43],"2021-08-30","2021-09-24","2020-10-01",35,[17,14,245],"Laxity; Skin",[139],{"nctId":248,"briefTitle":181,"status":60,"phases":249,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":254},"NCT02724644",[43],"2016-09","2016-02",375,[17,14],[166],{"trials":256,"activeCount":52},[257,267,276],{"nctId":258,"briefTitle":259,"status":60,"phases":260,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":266},"NCT00528840","Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease",[44],"2008-10","2007-10",201,[265],"Advanced Dupuytren's Disease",[139],{"nctId":268,"briefTitle":269,"status":60,"phases":270,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":275},"NCT00528606","AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture",[44],"2008-04","2007-08",308,[22],[139],{"nctId":277,"briefTitle":278,"status":60,"phases":279,"primaryCompletion":280,"completion":280,"start":272,"enrollment":281,"conditions":282,"interventions":283},"NCT00533273","Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease",[44],"2008-09",66,[265],[139],{"trials":285,"activeCount":52},[286],{"nctId":287,"briefTitle":288,"status":60,"phases":289,"primaryCompletion":213,"completion":213,"start":290,"enrollment":291,"conditions":292,"interventions":293},"NCT01498640","Retreatment of Recurrent Dupuytren's Contractures",[45],"2012-03",52,[195],[197],{"trials":295,"activeCount":52},[],{"intervention":297,"totalTrials":298,"cells":299},"Lidoderm",5,{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":326,"PHASE4":328,"NA":360},{"trials":301,"activeCount":52},[],{"trials":303,"activeCount":52},[],{"trials":305,"activeCount":52},[306,316],{"nctId":307,"briefTitle":308,"status":60,"phases":309,"primaryCompletion":310,"completion":261,"start":311,"enrollment":312,"conditions":313,"interventions":315},"NCT00589979","Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee",[43],"2008-06","2007-03",169,[314],"Osteoarthritis of the Knee",[297],{"nctId":317,"briefTitle":318,"status":60,"phases":319,"primaryCompletion":320,"start":321,"enrollment":322,"conditions":323,"interventions":325},"NCT00904462","Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee",[43],"2005-09","2004-08",224,[324],"Osteoarthritis, Knee",[297],{"trials":327,"activeCount":52},[],{"trials":329,"activeCount":52},[330,342,351],{"nctId":331,"briefTitle":332,"status":60,"phases":333,"primaryCompletion":334,"start":335,"enrollment":336,"conditions":337,"interventions":341},"NCT00904020","A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain",[45],"2002-11","2002-06",107,[338,339,340],"Postherpetic Neuralgia","Diabetic Neuropathy","Low Back Pain",[297],{"nctId":343,"briefTitle":344,"status":60,"phases":345,"primaryCompletion":346,"start":347,"enrollment":193,"conditions":348,"interventions":350},"NCT00903851","Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy",[45],"2003-06","2002-04",[349],"Diabetes",[297],{"nctId":352,"briefTitle":353,"status":70,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"conditions":357,"interventions":358},"NCT00904605","Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee",[45],"2004-11","2004-06",[314],[297,359],"Celecoxib",{"trials":361,"activeCount":52},[],{"intervention":363,"totalTrials":29,"cells":364},"Oxymorphone ER",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":403,"NA":417},{"trials":366,"activeCount":52},[],{"trials":368,"activeCount":52},[],{"trials":370,"activeCount":52},[],{"trials":372,"activeCount":52},[373,382,392],{"nctId":374,"briefTitle":375,"status":70,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":381},"NCT00765856","Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects",[44],"2010-02-22","2008-11-17",27,[25],[363],{"nctId":383,"briefTitle":384,"status":60,"phases":385,"primaryCompletion":386,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":391},"NCT00904449","Open Label Assessment of Long-Term Safety and Utility",[44],"2002-12","2001-04",24,[390],"Pain",[363],{"nctId":393,"briefTitle":394,"status":60,"phases":395,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":402},"NCT00904280","Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy",[44],"2003-07","2001-03",239,[400,401],"Cancers, Pain","Lower Back Pain",[363],{"trials":404,"activeCount":52},[405],{"nctId":406,"briefTitle":407,"status":60,"phases":408,"primaryCompletion":409,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":414},"NCT00955110","Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)",[45],"2009-09","2009-06",78,[413],"Healthy",[363,415,416],"Oxycodone CR","Hydromorphone",{"trials":418,"activeCount":52},[],{"intervention":420,"totalTrials":29,"cells":421},"Lidoderm®",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":437,"PHASE4":439,"NA":467},{"trials":423,"activeCount":52},[],{"trials":425,"activeCount":52},[],{"trials":427,"activeCount":52},[428],{"nctId":429,"briefTitle":430,"status":60,"phases":431,"primaryCompletion":432,"start":321,"enrollment":433,"conditions":434,"interventions":436},"NCT00904111","A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain",[43],"2005-10",215,[435],"Chronic Low Back Pain",[420],{"trials":438,"activeCount":52},[],{"trials":440,"activeCount":52},[441,451,459],{"nctId":442,"briefTitle":443,"status":60,"phases":444,"primaryCompletion":445,"start":446,"enrollment":447,"conditions":448,"interventions":450},"NCT00904540","Topical Lidocaine Patch in Low Back Pain",[45],"2002-10","2002-03",131,[449],"Acute and Chronic Non-radicular LBP",[420],{"nctId":452,"briefTitle":453,"status":70,"phases":454,"primaryCompletion":355,"start":455,"enrollment":456,"conditions":457,"interventions":458},"NCT00904397","Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain",[45],"2004-07",98,[435],[420,359],{"nctId":460,"briefTitle":461,"status":60,"phases":462,"primaryCompletion":463,"start":463,"enrollment":464,"conditions":465,"interventions":466},"NCT00904475","Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain",[45],"2003-04",102,[435],[420,420],{"trials":468,"activeCount":52},[],{"intervention":470,"totalTrials":471,"cells":472},"CCH-aaes",3,{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":490,"PHASE4":501,"NA":514},{"trials":474,"activeCount":52},[],{"trials":476,"activeCount":52},[],{"trials":478,"activeCount":52},[479],{"nctId":480,"briefTitle":481,"status":60,"phases":482,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":488},"NCT05419505","Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks",[43],"2023-01-03","2023-06-21","2022-06-15",91,[17,14],[470,489],"Antifibrinolytic Agent",{"trials":491,"activeCount":52},[492],{"nctId":493,"briefTitle":494,"status":60,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":500},"NCT03526549","Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)",[44],"2021-10-08","2018-04-26",483,[17,14],[470],{"trials":502,"activeCount":52},[503],{"nctId":504,"briefTitle":505,"status":60,"phases":506,"primaryCompletion":507,"completion":508,"start":509,"enrollment":9,"conditions":510,"interventions":511},"NCT04677712","Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite",[45],"2021-06-26","2021-09-02","2020-12-28",[33,14],[470,512,513],"Arnica Gel","INhance®",{"trials":515,"activeCount":52},[],{"intervention":517,"totalTrials":518,"cells":519},"Frovatriptan",2,{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":537,"NA":549},{"trials":521,"activeCount":52},[],{"trials":523,"activeCount":52},[],{"trials":525,"activeCount":52},[],{"trials":527,"activeCount":52},[528],{"nctId":529,"briefTitle":530,"status":60,"phases":531,"primaryCompletion":335,"completion":335,"start":532,"enrollment":533,"conditions":534,"interventions":536},"NCT00644033","A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine",[44],"2001-06",579,[535],"Menstrually Associated Migraine",[517,517],{"trials":538,"activeCount":52},[539],{"nctId":540,"briefTitle":541,"status":60,"phases":542,"primaryCompletion":543,"completion":543,"start":320,"enrollment":544,"conditions":545,"interventions":547},"NCT00904098","Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine",[45],"2006-02",192,[546],"Menstrual Migraine (MM) Headaches",[517,548],"Usual Care",{"trials":550,"activeCount":52},[],{"intervention":359,"totalTrials":518,"cells":552},{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":561,"NA":571},{"trials":554,"activeCount":52},[],{"trials":556,"activeCount":52},[],{"trials":558,"activeCount":52},[],{"trials":560,"activeCount":52},[],{"trials":562,"activeCount":52},[563,567],{"nctId":352,"briefTitle":353,"status":70,"phases":564,"primaryCompletion":355,"completion":355,"start":356,"conditions":565,"interventions":566},[45],[314],[297,359],{"nctId":452,"briefTitle":453,"status":70,"phases":568,"primaryCompletion":355,"start":455,"enrollment":456,"conditions":569,"interventions":570},[45],[435],[420,359],{"trials":572,"activeCount":52},[],{"intervention":574,"totalTrials":8,"cells":575},"Gabapentin + Placebo",{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":584,"NA":602},{"trials":577,"activeCount":52},[],{"trials":579,"activeCount":52},[],{"trials":581,"activeCount":52},[],{"trials":583,"activeCount":52},[],{"trials":585,"activeCount":52},[586],{"nctId":587,"briefTitle":588,"status":60,"phases":589,"primaryCompletion":346,"start":590,"enrollment":591,"conditions":592,"interventions":598},"NCT00904202","A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions",[45],"2003-01",62,[338,339,593,594,595,596,597],"Complex Regional Pain Syndrome","Carpal Tunnel Syndrome","HIV Neuropathy","Idiopathic Sensory Neuropathy","Peripheral Neuropathy",[574,599,600,601],"Gabapentin + Lidoderm®","Gabapentin 300 mg capsules 1800 mg\u002Fday + placebo patch","Gabapentin 1800 mg\u002Fday + Lidoderm patch",{"trials":603,"activeCount":52},[],{"intervention":599,"totalTrials":8,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":614,"NA":620},{"trials":607,"activeCount":52},[],{"trials":609,"activeCount":52},[],{"trials":611,"activeCount":52},[],{"trials":613,"activeCount":52},[],{"trials":615,"activeCount":52},[616],{"nctId":587,"briefTitle":588,"status":60,"phases":617,"primaryCompletion":346,"start":590,"enrollment":591,"conditions":618,"interventions":619},[45],[338,339,593,594,595,596,597],[574,599,600,601],{"trials":621,"activeCount":52},[],{"intervention":600,"totalTrials":8,"cells":623},{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":638},{"trials":625,"activeCount":52},[],{"trials":627,"activeCount":52},[],{"trials":629,"activeCount":52},[],{"trials":631,"activeCount":52},[],{"trials":633,"activeCount":52},[634],{"nctId":587,"briefTitle":588,"status":60,"phases":635,"primaryCompletion":346,"start":590,"enrollment":591,"conditions":636,"interventions":637},[45],[338,339,593,594,595,596,597],[574,599,600,601],{"trials":639,"activeCount":52},[],{"intervention":601,"totalTrials":8,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":656},{"trials":643,"activeCount":52},[],{"trials":645,"activeCount":52},[],{"trials":647,"activeCount":52},[],{"trials":649,"activeCount":52},[],{"trials":651,"activeCount":52},[652],{"nctId":587,"briefTitle":588,"status":60,"phases":653,"primaryCompletion":346,"start":590,"enrollment":591,"conditions":654,"interventions":655},[45],[338,339,593,594,595,596,597],[574,599,600,601],{"trials":657,"activeCount":52},[],{"intervention":548,"totalTrials":8,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":674},{"trials":661,"activeCount":52},[],{"trials":663,"activeCount":52},[],{"trials":665,"activeCount":52},[],{"trials":667,"activeCount":52},[],{"trials":669,"activeCount":52},[670],{"nctId":540,"briefTitle":541,"status":60,"phases":671,"primaryCompletion":543,"completion":543,"start":320,"enrollment":544,"conditions":672,"interventions":673},[45],[546],[517,548],{"trials":675,"activeCount":52},[],{"intervention":415,"totalTrials":8,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":692},{"trials":679,"activeCount":52},[],{"trials":681,"activeCount":52},[],{"trials":683,"activeCount":52},[],{"trials":685,"activeCount":52},[],{"trials":687,"activeCount":52},[688],{"nctId":406,"briefTitle":407,"status":60,"phases":689,"primaryCompletion":409,"completion":409,"start":410,"enrollment":411,"conditions":690,"interventions":691},[45],[413],[363,415,416],{"trials":693,"activeCount":52},[],{"intervention":416,"totalTrials":8,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":702,"PHASE4":704,"NA":710},{"trials":697,"activeCount":52},[],{"trials":699,"activeCount":52},[],{"trials":701,"activeCount":52},[],{"trials":703,"activeCount":52},[],{"trials":705,"activeCount":52},[706],{"nctId":406,"briefTitle":407,"status":60,"phases":707,"primaryCompletion":409,"completion":409,"start":410,"enrollment":411,"conditions":708,"interventions":709},[45],[413],[363,415,416],{"trials":711,"activeCount":52},[],{"intervention":713,"totalTrials":8,"cells":714},"Aveed Injectable Product",{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":721,"PHASE4":723,"NA":739},{"trials":716,"activeCount":52},[],{"trials":718,"activeCount":52},[],{"trials":720,"activeCount":52},[],{"trials":722,"activeCount":52},[],{"trials":724,"activeCount":52},[725],{"nctId":726,"briefTitle":727,"status":60,"phases":728,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":736},"NCT04456296","A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism",[45],"2023-07-12","2020-06-30",673,[733,734,735],"Hypogonadism","Hypogonadism, Male","Hypogonadotropic Hypogonadism",[713,737,738],"Fortesta","Testim",{"trials":740,"activeCount":52},[],{"intervention":737,"totalTrials":8,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":757},{"trials":744,"activeCount":52},[],{"trials":746,"activeCount":52},[],{"trials":748,"activeCount":52},[],{"trials":750,"activeCount":52},[],{"trials":752,"activeCount":52},[753],{"nctId":726,"briefTitle":727,"status":60,"phases":754,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":755,"interventions":756},[45],[733,734,735],[713,737,738],{"trials":758,"activeCount":52},[],{"intervention":738,"totalTrials":8,"cells":760},{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":769,"NA":775},{"trials":762,"activeCount":52},[],{"trials":764,"activeCount":52},[],{"trials":766,"activeCount":52},[],{"trials":768,"activeCount":52},[],{"trials":770,"activeCount":52},[771],{"nctId":726,"briefTitle":727,"status":60,"phases":772,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":773,"interventions":774},[45],[733,734,735],[713,737,738],{"trials":776,"activeCount":52},[],{"intervention":512,"totalTrials":8,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":785,"PHASE4":787,"NA":793},{"trials":780,"activeCount":52},[],{"trials":782,"activeCount":52},[],{"trials":784,"activeCount":52},[],{"trials":786,"activeCount":52},[],{"trials":788,"activeCount":52},[789],{"nctId":504,"briefTitle":505,"status":60,"phases":790,"primaryCompletion":507,"completion":508,"start":509,"enrollment":9,"conditions":791,"interventions":792},[45],[33,14],[470,512,513],{"trials":794,"activeCount":52},[],{"intervention":513,"totalTrials":8,"cells":796},{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":805,"NA":811},{"trials":798,"activeCount":52},[],{"trials":800,"activeCount":52},[],{"trials":802,"activeCount":52},[],{"trials":804,"activeCount":52},[],{"trials":806,"activeCount":52},[807],{"nctId":504,"briefTitle":505,"status":60,"phases":808,"primaryCompletion":507,"completion":508,"start":509,"enrollment":9,"conditions":809,"interventions":810},[45],[33,14],[470,512,513],{"trials":812,"activeCount":52},[],{"intervention":814,"totalTrials":11,"cells":815},"AA4500",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":840,"PHASE4":892,"NA":894},{"trials":817,"activeCount":52},[],{"trials":819,"activeCount":52},[],{"trials":821,"activeCount":52},[822,831],{"nctId":823,"briefTitle":824,"status":60,"phases":825,"primaryCompletion":826,"completion":826,"start":827,"enrollment":828,"conditions":829,"interventions":830},"NCT00755222","The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease",[43],"2009-12","2008-08",147,[19],[814],{"nctId":832,"briefTitle":833,"status":60,"phases":834,"primaryCompletion":835,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":839},"NCT01430169","Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease",[43],"2011-11","2011-09",20,[19],[814],{"trials":841,"activeCount":52},[842,851,860,870,878,886],{"nctId":843,"briefTitle":844,"status":60,"phases":845,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":850},"NCT01685437","A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease",[44],"2013-12","2012-09",189,[19],[814],{"nctId":852,"briefTitle":853,"status":60,"phases":854,"primaryCompletion":855,"completion":855,"start":856,"enrollment":857,"conditions":858,"interventions":859},"NCT01243411","A Study of AA4500 in Men With Peyronie's Disease",[44],"2012-08","2010-11",348,[19],[814],{"nctId":861,"briefTitle":862,"status":60,"phases":863,"primaryCompletion":864,"completion":865,"start":866,"enrollment":867,"conditions":868,"interventions":869},"NCT02267460","An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease",[44],"2015-10","2016-03","2014-10",30,[19],[814],{"nctId":871,"briefTitle":872,"status":60,"phases":873,"primaryCompletion":874,"completion":874,"start":875,"enrollment":103,"conditions":876,"interventions":877},"NCT01221597","Study of AA4500 in the Treatment of Peyronie's Disease",[44],"2012-04","2010-09",[19],[814],{"nctId":879,"briefTitle":880,"status":60,"phases":881,"primaryCompletion":882,"completion":882,"start":150,"enrollment":883,"conditions":884,"interventions":885},"NCT00528424","AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease",[44],"2008-11",286,[265],[814],{"nctId":887,"briefTitle":872,"status":60,"phases":888,"primaryCompletion":290,"completion":290,"start":889,"enrollment":103,"conditions":890,"interventions":891},"NCT01221623",[44],"2010-10",[19],[814],{"trials":893,"activeCount":52},[],{"trials":895,"activeCount":52},[],{"intervention":897,"totalTrials":29,"cells":898},"Oxymorphone Extended Release",{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":905,"PHASE4":947,"NA":949},{"trials":900,"activeCount":52},[],{"trials":902,"activeCount":52},[],{"trials":904,"activeCount":52},[],{"trials":906,"activeCount":52},[907,919,928,936],{"nctId":908,"briefTitle":909,"status":60,"phases":910,"primaryCompletion":911,"completion":912,"start":913,"enrollment":914,"conditions":915,"interventions":918},"NCT00911261","Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain",[44],"2005-03","2005-05","2003-08",223,[25,916,917],"Neuropathic Pain","Cancer",[897],{"nctId":920,"briefTitle":921,"status":60,"phases":922,"completion":923,"start":924,"enrollment":925,"conditions":926,"interventions":927},"NCT00226421","Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain",[44],"2005-08","2004-10",120,[25],[897],{"nctId":929,"briefTitle":930,"status":60,"phases":931,"completion":932,"start":355,"enrollment":933,"conditions":934,"interventions":935},"NCT00225797","Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain",[44],"2005-07",160,[25],[897],{"nctId":937,"briefTitle":938,"status":60,"phases":939,"primaryCompletion":940,"completion":941,"start":346,"enrollment":942,"conditions":943,"interventions":945},"NCT00911287","Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain",[44],"2004-01","2004-03",129,[390,944],"Chronic Disease",[946],"Oxymorphone extended release",{"trials":948,"activeCount":52},[],{"trials":950,"activeCount":52},[],{"intervention":952,"totalTrials":471,"cells":953},"pagoclone",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":980,"PHASE4":993,"NA":995},{"trials":955,"activeCount":52},[],{"trials":957,"activeCount":52},[],{"trials":959,"activeCount":52},[960,970],{"nctId":961,"briefTitle":962,"status":60,"phases":963,"primaryCompletion":964,"completion":965,"start":964,"enrollment":966,"conditions":967,"interventions":969},"NCT00370981","Exploratory Study of Pagoclone in Men With Premature Ejaculation.",[43],"2006-07","2006-10",100,[968],"Premature Ejaculation",[952],{"nctId":971,"briefTitle":972,"status":60,"phases":973,"primaryCompletion":974,"completion":974,"start":975,"enrollment":925,"conditions":976,"interventions":978},"NCT00216255","EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study",[43],"2011-07","2005-04",[977],"Persistent Developmental Stuttering",[979],"Pagoclone",{"trials":981,"activeCount":52},[982],{"nctId":983,"briefTitle":984,"status":60,"phases":985,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":990,"interventions":992},"NCT00830154","A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering",[43,44],"2010-01","2011-01","2009-02",321,[991],"Stuttering",[952],{"trials":994,"activeCount":52},[],{"trials":996,"activeCount":52},[],{"intervention":998,"totalTrials":471,"cells":999},"Oxymorphone IR",{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1034,"NA":1036},{"trials":1001,"activeCount":52},[],{"trials":1003,"activeCount":52},[],{"trials":1005,"activeCount":52},[],{"trials":1007,"activeCount":52},[1008,1016,1024],{"nctId":1009,"briefTitle":1010,"status":1011,"phases":1012,"primaryCompletion":846,"completion":846,"start":889,"enrollment":52,"conditions":1013,"interventions":1014},"NCT01206907","Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects","WITHDRAWN",[44],[25],[1015],"oxymorphone IR",{"nctId":1017,"briefTitle":1018,"status":60,"phases":1019,"primaryCompletion":346,"completion":346,"start":463,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT00904085","Post-operative Efficacy and Safety Study",[44],122,[1022],"Post-operative Pain",[998],{"nctId":1025,"briefTitle":1026,"status":60,"phases":1027,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":1030,"conditions":1031,"interventions":1033},"NCT00801398","Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.",[44],"2011-04-18","2009-02-17",58,[1032],"Postoperative Pain",[998],{"trials":1035,"activeCount":52},[],{"trials":1037,"activeCount":52},[],{"intervention":1039,"totalTrials":518,"cells":1040},"Octreotide",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1057,"PHASE4":1069,"NA":1071},{"trials":1042,"activeCount":52},[],{"trials":1044,"activeCount":52},[],{"trials":1046,"activeCount":52},[1047],{"nctId":1048,"briefTitle":1049,"status":70,"phases":1050,"primaryCompletion":835,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1056},"NCT00884715","Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome",[42,43],"2011-12","2009-07",10,[1055],"Carcinoid Syndrome",[1039],{"trials":1058,"activeCount":52},[1059],{"nctId":1060,"briefTitle":1061,"status":70,"phases":1062,"primaryCompletion":874,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1068},"NCT01295060","Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly",[44],"2012-06","2011-02",12,[1067],"Acromegaly",[1039],{"trials":1070,"activeCount":52},[],{"trials":1072,"activeCount":52},[],{"intervention":1074,"totalTrials":518,"cells":1075},"oxymorphone HCl",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1107,"NA":1109},{"trials":1077,"activeCount":52},[],{"trials":1079,"activeCount":52},[],{"trials":1081,"activeCount":52},[],{"trials":1083,"activeCount":52},[1084,1094],{"nctId":1085,"briefTitle":1086,"status":60,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1093},"NCT01210352","Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects",[44],"2017-10-06","2010-12-13",61,[1092],"Post Operative Pain",[1074],{"nctId":1095,"briefTitle":1096,"status":70,"phases":1097,"primaryCompletion":1098,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1105},"NCT02687451","Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects",[44],"2020-07-01","2020-09-15","2016-04",28,[1103,1104],"Post-Operative Pain","Acute Pain",[1106],"Oxymorphone HCl",{"trials":1108,"activeCount":52},[],{"trials":1110,"activeCount":52},[],{"intervention":1112,"totalTrials":8,"cells":1113},"Testosterone Undecanoate 750 mg",{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1120,"PHASE4":1133,"NA":1135},{"trials":1115,"activeCount":52},[],{"trials":1117,"activeCount":52},[],{"trials":1119,"activeCount":52},[],{"trials":1121,"activeCount":52},[1122],{"nctId":1123,"briefTitle":1124,"status":60,"phases":1125,"primaryCompletion":1052,"completion":1052,"start":1126,"enrollment":1127,"conditions":1128,"interventions":1131},"NCT00467870","Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men",[44],"2006-03",531,[733,1129,1130],"Primary Hypogonadism","Secondary Hypogonadism",[1112,1132],"Testosterone Undecanoate 1000 mg",{"trials":1134,"activeCount":52},[],{"trials":1136,"activeCount":52},[],{"intervention":1132,"totalTrials":8,"cells":1138},{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1151,"NA":1153},{"trials":1140,"activeCount":52},[],{"trials":1142,"activeCount":52},[],{"trials":1144,"activeCount":52},[],{"trials":1146,"activeCount":52},[1147],{"nctId":1123,"briefTitle":1124,"status":60,"phases":1148,"primaryCompletion":1052,"completion":1052,"start":1126,"enrollment":1127,"conditions":1149,"interventions":1150},[44],[733,1129,1130],[1112,1132],{"trials":1152,"activeCount":52},[],{"trials":1154,"activeCount":52},[],{"intervention":1156,"totalTrials":8,"cells":1157},"Testosterone",{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1164,"PHASE4":1173,"NA":1175},{"trials":1159,"activeCount":52},[],{"trials":1161,"activeCount":52},[],{"trials":1163,"activeCount":52},[],{"trials":1165,"activeCount":52},[1166],{"nctId":1167,"briefTitle":1168,"status":60,"phases":1169,"primaryCompletion":151,"completion":151,"start":272,"enrollment":1170,"conditions":1171,"interventions":1172},"NCT00522431","A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone",[44],149,[733],[1156],{"trials":1174,"activeCount":52},[],{"trials":1176,"activeCount":52},[],{"intervention":1178,"totalTrials":8,"cells":1179},"Frovatriptan 2.5 mg",{"EARLY_PHASE1":1180,"PHASE1":1182,"PHASE2":1184,"PHASE3":1186,"PHASE4":1198,"NA":1200},{"trials":1181,"activeCount":52},[],{"trials":1183,"activeCount":52},[],{"trials":1185,"activeCount":52},[],{"trials":1187,"activeCount":52},[1188],{"nctId":1189,"briefTitle":1190,"status":60,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":1194,"conditions":1195,"interventions":1197},"NCT01035983","Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches",[44],"2005-06","2003-12",550,[1196],"Migraine",[1178],{"trials":1199,"activeCount":52},[],{"trials":1201,"activeCount":52},[],{"intervention":1203,"totalTrials":8,"cells":1204},"testosterone gel 2%",{"EARLY_PHASE1":1205,"PHASE1":1207,"PHASE2":1209,"PHASE3":1211,"PHASE4":1222,"NA":1224},{"trials":1206,"activeCount":52},[],{"trials":1208,"activeCount":52},[],{"trials":1210,"activeCount":52},[],{"trials":1212,"activeCount":52},[1213],{"nctId":1214,"briefTitle":1215,"status":60,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":856,"enrollment":1218,"conditions":1219,"interventions":1221},"NCT01228071","Time to Eugonadal Range, Time to Steady State and Drying Time",[44],"2011-05",34,[1220],"Male Hypogonadism",[1203],{"trials":1223,"activeCount":52},[],{"trials":1225,"activeCount":52},[],{"intervention":1227,"totalTrials":8,"cells":1228},"Oxymorphone hydrochloride",{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1235,"PHASE4":1248,"NA":1250},{"trials":1230,"activeCount":52},[],{"trials":1232,"activeCount":52},[],{"trials":1234,"activeCount":52},[],{"trials":1236,"activeCount":52},[1237],{"nctId":1238,"briefTitle":1239,"status":1240,"phases":1241,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":140,"conditions":1245,"interventions":1247},"NCT04681027","Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children","SUSPENDED",[44],"2017-04-04","2021-01","2013-03-11",[25,1246],"Postsurgical Pain",[1227],{"trials":1249,"activeCount":52},[],{"trials":1251,"activeCount":52},[],{"intervention":1253,"totalTrials":8,"cells":1254},"Histrelin hydrogel implant",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1261,"PHASE4":1275,"NA":1277},{"trials":1256,"activeCount":52},[],{"trials":1258,"activeCount":52},[],{"trials":1260,"activeCount":52},[],{"trials":1262,"activeCount":52},[1263],{"nctId":1264,"briefTitle":1265,"status":60,"phases":1266,"primaryCompletion":1267,"completion":1193,"start":1268,"enrollment":1269,"conditions":1270,"interventions":1273},"NCT01394263","Study of Histrelin Subdermal Implant in Patients With Prostate Cancer",[44],"2001-12","2000-05",59,[1271,1272],"Prostate Cancer","Adenocarcinoma of the Prostate",[1253,1274],"Zoladex goserelin implant",{"trials":1276,"activeCount":52},[],{"trials":1278,"activeCount":52},[],{"intervention":1274,"totalTrials":8,"cells":1280},{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1287,"PHASE4":1293,"NA":1295},{"trials":1282,"activeCount":52},[],{"trials":1284,"activeCount":52},[],{"trials":1286,"activeCount":52},[],{"trials":1288,"activeCount":52},[1289],{"nctId":1264,"briefTitle":1265,"status":60,"phases":1290,"primaryCompletion":1267,"completion":1193,"start":1268,"enrollment":1269,"conditions":1291,"interventions":1292},[44],[1271,1272],[1253,1274],{"trials":1294,"activeCount":52},[],{"trials":1296,"activeCount":52},[],{"intervention":1298,"totalTrials":8,"cells":1299},"histrelin acetate",{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1316,"NA":1318},{"trials":1301,"activeCount":52},[],{"trials":1303,"activeCount":52},[],{"trials":1305,"activeCount":52},[],{"trials":1307,"activeCount":52},[1308],{"nctId":1309,"briefTitle":1310,"status":60,"phases":1311,"primaryCompletion":913,"completion":924,"start":1312,"enrollment":1313,"conditions":1314,"interventions":1315},"NCT01697384","Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer",[44],"2000-04",138,[1271,1272],[1298],{"trials":1317,"activeCount":52},[],{"trials":1319,"activeCount":52},[],{"intervention":1321,"totalTrials":8,"cells":1322},"EN3285",{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1327,"PHASE3":1329,"PHASE4":1340,"NA":1342},{"trials":1324,"activeCount":52},[],{"trials":1326,"activeCount":52},[],{"trials":1328,"activeCount":52},[],{"trials":1330,"activeCount":52},[1331],{"nctId":1332,"briefTitle":1333,"status":70,"phases":1334,"primaryCompletion":410,"completion":410,"start":150,"enrollment":1335,"conditions":1336,"interventions":1339},"NCT00574860","EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer",[44],240,[1337,1338],"Oral Mucositis","Head and Neck Cancer",[1321],{"trials":1341,"activeCount":52},[],{"trials":1343,"activeCount":52},[],{"intervention":1345,"totalTrials":8,"cells":1346},"XIAFLEX \u002F XIAPEX",{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1363,"NA":1365},{"trials":1348,"activeCount":52},[],{"trials":1350,"activeCount":52},[],{"trials":1352,"activeCount":52},[],{"trials":1354,"activeCount":52},[1355],{"nctId":1356,"briefTitle":1357,"status":60,"phases":1358,"primaryCompletion":1359,"completion":1359,"start":847,"enrollment":1360,"conditions":1361,"interventions":1362},"NCT01674634","Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures",[44],"2013-07",715,[22],[1345],{"trials":1364,"activeCount":52},[],{"trials":1366,"activeCount":52},[],{"intervention":1368,"totalTrials":8,"cells":1369},"Octreotide Implant",{"EARLY_PHASE1":1370,"PHASE1":1372,"PHASE2":1374,"PHASE3":1376,"PHASE4":1386,"NA":1388},{"trials":1371,"activeCount":52},[],{"trials":1373,"activeCount":52},[],{"trials":1375,"activeCount":52},[],{"trials":1377,"activeCount":52},[1378],{"nctId":1379,"briefTitle":1380,"status":70,"phases":1381,"primaryCompletion":1064,"completion":1382,"start":280,"enrollment":312,"conditions":1383,"interventions":1384},"NCT00765323","Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly",[44],"2011-06",[1067],[1368,1385],"Sandostatin LAR Depot",{"trials":1387,"activeCount":52},[],{"trials":1389,"activeCount":52},[],{"intervention":1385,"totalTrials":8,"cells":1391},{"EARLY_PHASE1":1392,"PHASE1":1394,"PHASE2":1396,"PHASE3":1398,"PHASE4":1404,"NA":1406},{"trials":1393,"activeCount":52},[],{"trials":1395,"activeCount":52},[],{"trials":1397,"activeCount":52},[],{"trials":1399,"activeCount":52},[1400],{"nctId":1379,"briefTitle":1380,"status":70,"phases":1401,"primaryCompletion":1064,"completion":1382,"start":280,"enrollment":312,"conditions":1402,"interventions":1403},[44],[1067],[1368,1385],{"trials":1405,"activeCount":52},[],{"trials":1407,"activeCount":52},[],{"intervention":1409,"totalTrials":8,"cells":1410},"PRO 2000\u002F5",{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1430,"NA":1432},{"trials":1412,"activeCount":52},[],{"trials":1414,"activeCount":52},[],{"trials":1416,"activeCount":52},[],{"trials":1418,"activeCount":52},[1419],{"nctId":1420,"briefTitle":1421,"status":60,"phases":1422,"primaryCompletion":827,"completion":409,"start":432,"enrollment":1423,"conditions":1424,"interventions":1429},"NCT00262106","Trial to Evaluate PRO 2000\u002F5 Gels for the Prevention of Vaginally Acquired HIV Infection",[44],9404,[1425,1426,1427,1428],"HIV Infections","Gonorrhea","Chlamydial Infections","Genital Herpes",[1409],{"trials":1431,"activeCount":52},[],{"trials":1433,"activeCount":52},[],{"intervention":1435,"totalTrials":8,"cells":1436},"Histrelin Subcutaneous Implant",{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1443,"PHASE4":1455,"NA":1457},{"trials":1438,"activeCount":52},[],{"trials":1440,"activeCount":52},[],{"trials":1442,"activeCount":52},[],{"trials":1444,"activeCount":52},[1445],{"nctId":1446,"briefTitle":1447,"status":60,"phases":1448,"primaryCompletion":1449,"completion":874,"start":1450,"enrollment":1451,"conditions":1452,"interventions":1454},"NCT00779103","Histrelin Subcutaneous Implant in Children With Central Precocious Puberty",[44],"2011-08","2004-09",36,[1453],"Central Precocious Puberty",[1435],{"trials":1456,"activeCount":52},[],{"trials":1458,"activeCount":52},[],{"intervention":1460,"totalTrials":8,"cells":1461},"VALSTAR - Maintenance Therapy",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1468,"PHASE4":1479,"NA":1481},{"trials":1463,"activeCount":52},[],{"trials":1465,"activeCount":52},[],{"trials":1467,"activeCount":52},[],{"trials":1469,"activeCount":52},[1470],{"nctId":1471,"briefTitle":1472,"status":70,"phases":1473,"primaryCompletion":162,"completion":162,"start":1217,"enrollment":8,"conditions":1474,"interventions":1478},"NCT01310803","Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder",[44],[1475,1476,1477],"Carcinoma in Situ","Transitional Cell Carcinoma","Non-muscle Invasive Bladder Cancer",[1460],{"trials":1480,"activeCount":52},[],{"trials":1482,"activeCount":52},[],{"intervention":1484,"totalTrials":8,"cells":1485},"AA4500 collagenase clostridium histolyticum",{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1502,"NA":1504},{"trials":1487,"activeCount":52},[],{"trials":1489,"activeCount":52},[],{"trials":1491,"activeCount":52},[],{"trials":1493,"activeCount":52},[1494],{"nctId":1495,"briefTitle":1496,"status":60,"phases":1497,"primaryCompletion":1498,"completion":1498,"start":836,"enrollment":1499,"conditions":1500,"interventions":1501},"NCT01407068","Administration of Two Injections for Multiple Dupuytren's Contractures",[44],"2012-02",60,[22],[1484],{"trials":1503,"activeCount":52},[],{"trials":1505,"activeCount":52},[],{"intervention":1507,"totalTrials":8,"cells":1508},"Oxymorphone immediate release",{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1515,"PHASE4":1524,"NA":1526},{"trials":1510,"activeCount":52},[],{"trials":1512,"activeCount":52},[],{"trials":1514,"activeCount":52},[],{"trials":1516,"activeCount":52},[1517],{"nctId":1518,"briefTitle":1519,"status":60,"phases":1520,"completion":923,"start":1450,"enrollment":1521,"conditions":1522,"interventions":1523},"NCT00226395","Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain",[44],320,[1104],[1507],{"trials":1525,"activeCount":52},[],{"trials":1527,"activeCount":52},[],{"intervention":1529,"totalTrials":8,"cells":1530},"Valrubicin, 800 mg",{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1549,"NA":1551},{"trials":1532,"activeCount":52},[],{"trials":1534,"activeCount":52},[],{"trials":1536,"activeCount":52},[],{"trials":1538,"activeCount":52},[1539],{"nctId":1540,"briefTitle":1541,"status":60,"phases":1542,"primaryCompletion":1543,"completion":1543,"start":1544,"enrollment":1545,"conditions":1546,"interventions":1548},"NCT01316874","Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)",[43,44],"1997-04","1993-11",90,[1475,1547],"Bladder Cancer",[1529],{"trials":1550,"activeCount":52},[],{"trials":1552,"activeCount":52},[],{"intervention":1554,"totalTrials":8,"cells":1555},"lidocaine patch 5%",{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1562,"PHASE4":1573,"NA":1575},{"trials":1557,"activeCount":52},[],{"trials":1559,"activeCount":52},[],{"trials":1561,"activeCount":52},[],{"trials":1563,"activeCount":52},[1564],{"nctId":1565,"briefTitle":1566,"status":70,"phases":1567,"primaryCompletion":1568,"completion":1568,"start":1569,"enrollment":1570,"conditions":1571,"interventions":1572},"NCT00266214","Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome",[44],"2007-01","2005-11",210,[594],[1554],{"trials":1574,"activeCount":52},[],{"trials":1576,"activeCount":52},[],{"intervention":1578,"totalTrials":8,"cells":1579},"Frovatriptan 2.5mg QD",{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1586,"PHASE4":1596,"NA":1598},{"trials":1581,"activeCount":52},[],{"trials":1583,"activeCount":52},[],{"trials":1585,"activeCount":52},[],{"trials":1587,"activeCount":52},[1588],{"nctId":1589,"briefTitle":1590,"status":60,"phases":1591,"primaryCompletion":1126,"completion":1126,"start":924,"enrollment":1592,"conditions":1593,"interventions":1594},"NCT00475514","A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine",[44],500,[1196],[1578,1595],"Frovatriptan 2.5 mg BID",{"trials":1597,"activeCount":52},[],{"trials":1599,"activeCount":52},[],{"intervention":1595,"totalTrials":8,"cells":1601},{"EARLY_PHASE1":1602,"PHASE1":1604,"PHASE2":1606,"PHASE3":1608,"PHASE4":1614,"NA":1616},{"trials":1603,"activeCount":52},[],{"trials":1605,"activeCount":52},[],{"trials":1607,"activeCount":52},[],{"trials":1609,"activeCount":52},[1610],{"nctId":1589,"briefTitle":1590,"status":60,"phases":1611,"primaryCompletion":1126,"completion":1126,"start":924,"enrollment":1592,"conditions":1612,"interventions":1613},[44],[1196],[1578,1595],{"trials":1615,"activeCount":52},[],{"trials":1617,"activeCount":52},[],{"intervention":1619,"totalTrials":8,"cells":1620},"octreotide acetate",{"EARLY_PHASE1":1621,"PHASE1":1623,"PHASE2":1625,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1622,"activeCount":52},[],{"trials":1624,"activeCount":52},[],{"trials":1626,"activeCount":52},[1627],{"nctId":1628,"briefTitle":1629,"status":60,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1218,"conditions":1633,"interventions":1634},"NCT00913055","Open Label Study of Octreotide Implant in Patients With Acromegaly",[43],"2007-05","2007-02",[1067],[1619],{"trials":1636,"activeCount":52},[],{"trials":1638,"activeCount":52},[],{"trials":1640,"activeCount":52},[],{"intervention":489,"totalTrials":8,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1644,"activeCount":52},[],{"trials":1646,"activeCount":52},[],{"trials":1648,"activeCount":52},[1649],{"nctId":480,"briefTitle":481,"status":60,"phases":1650,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":1651,"interventions":1652},[43],[17,14],[470,489],{"trials":1654,"activeCount":52},[],{"trials":1656,"activeCount":52},[],{"trials":1658,"activeCount":52},[],{"intervention":1660,"totalTrials":8,"cells":1661},"trospium chloride inhalation powder",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1677,"PHASE4":1679,"NA":1681},{"trials":1663,"activeCount":52},[],{"trials":1665,"activeCount":52},[],{"trials":1667,"activeCount":52},[1668],{"nctId":1669,"briefTitle":1670,"status":60,"phases":1671,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":388,"conditions":1674,"interventions":1676},"NCT00465959","Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease",[42,43],"2007-06","2007-04",[1675],"Chronic Obstructive Pulmonary Disease",[1660],{"trials":1678,"activeCount":52},[],{"trials":1680,"activeCount":52},[],{"trials":1682,"activeCount":52},[],{"intervention":1684,"totalTrials":8,"cells":1685},"Collagenase Clostridium Histolyticum Single Injection Technique",{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1687,"activeCount":52},[],{"trials":1689,"activeCount":52},[],{"trials":1691,"activeCount":52},[1692],{"nctId":1693,"briefTitle":1694,"status":60,"phases":1695,"primaryCompletion":1696,"completion":1697,"start":1698,"enrollment":1053,"conditions":1699,"interventions":1701},"NCT04236635","Histopathology Following CCH Injection",[43],"2020-09-23","2020-10-26","2019-12-20",[1700],"Characteristics of Subcutaneous Tissue",[1684,1702],"Collagenase Clostridium Histolyticum Multiple Injection Technique",{"trials":1704,"activeCount":52},[],{"trials":1706,"activeCount":52},[],{"trials":1708,"activeCount":52},[],{"intervention":1702,"totalTrials":8,"cells":1710},{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1715,"PHASE3":1721,"PHASE4":1723,"NA":1725},{"trials":1712,"activeCount":52},[],{"trials":1714,"activeCount":52},[],{"trials":1716,"activeCount":52},[1717],{"nctId":1693,"briefTitle":1694,"status":60,"phases":1718,"primaryCompletion":1696,"completion":1697,"start":1698,"enrollment":1053,"conditions":1719,"interventions":1720},[43],[1700],[1684,1702],{"trials":1722,"activeCount":52},[],{"trials":1724,"activeCount":52},[],{"trials":1726,"activeCount":52},[],{"intervention":1728,"totalTrials":8,"cells":1729},"AA4500 0.29 mg\u002F1 mL",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1746,"PHASE4":1748,"NA":1750},{"trials":1731,"activeCount":52},[],{"trials":1733,"activeCount":52},[],{"trials":1735,"activeCount":52},[1736],{"nctId":1737,"briefTitle":1738,"status":60,"phases":1739,"primaryCompletion":161,"completion":161,"start":835,"enrollment":1740,"conditions":1741,"interventions":1742},"NCT01483963","AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder",[43],50,[28,31],[1728,1743,1744,1745],"AA4500 0.58 mg\u002F2 mL","AA4500 0.58 mg\u002F1 mL","AA4500 0.58 mg\u002F0.5 mL",{"trials":1747,"activeCount":52},[],{"trials":1749,"activeCount":52},[],{"trials":1751,"activeCount":52},[],{"intervention":1743,"totalTrials":8,"cells":1753},{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1764,"PHASE4":1766,"NA":1768},{"trials":1755,"activeCount":52},[],{"trials":1757,"activeCount":52},[],{"trials":1759,"activeCount":52},[1760],{"nctId":1737,"briefTitle":1738,"status":60,"phases":1761,"primaryCompletion":161,"completion":161,"start":835,"enrollment":1740,"conditions":1762,"interventions":1763},[43],[28,31],[1728,1743,1744,1745],{"trials":1765,"activeCount":52},[],{"trials":1767,"activeCount":52},[],{"trials":1769,"activeCount":52},[],{"intervention":1744,"totalTrials":8,"cells":1771},{"EARLY_PHASE1":1772,"PHASE1":1774,"PHASE2":1776,"PHASE3":1782,"PHASE4":1784,"NA":1786},{"trials":1773,"activeCount":52},[],{"trials":1775,"activeCount":52},[],{"trials":1777,"activeCount":52},[1778],{"nctId":1737,"briefTitle":1738,"status":60,"phases":1779,"primaryCompletion":161,"completion":161,"start":835,"enrollment":1740,"conditions":1780,"interventions":1781},[43],[28,31],[1728,1743,1744,1745],{"trials":1783,"activeCount":52},[],{"trials":1785,"activeCount":52},[],{"trials":1787,"activeCount":52},[],{"intervention":1745,"totalTrials":8,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1800,"PHASE4":1802,"NA":1804},{"trials":1791,"activeCount":52},[],{"trials":1793,"activeCount":52},[],{"trials":1795,"activeCount":52},[1796],{"nctId":1737,"briefTitle":1738,"status":60,"phases":1797,"primaryCompletion":161,"completion":161,"start":835,"enrollment":1740,"conditions":1798,"interventions":1799},[43],[28,31],[1728,1743,1744,1745],{"trials":1801,"activeCount":52},[],{"trials":1803,"activeCount":52},[],{"trials":1805,"activeCount":52},[],{"intervention":1807,"totalTrials":8,"cells":1808},"Megestrol acetate oral suspension nanocrystal dispersion 115 mg\u002FmL",{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1828,"PHASE4":1830,"NA":1832},{"trials":1810,"activeCount":52},[],{"trials":1812,"activeCount":52},[],{"trials":1814,"activeCount":52},[1815],{"nctId":1816,"briefTitle":1817,"status":60,"phases":1818,"primaryCompletion":1192,"completion":1192,"start":1819,"enrollment":1820,"conditions":1821,"interventions":1826},"NCT00637572","Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss",[43],"2004-12",63,[1425,1822,1823,1824,1825],"Cachexia","Anorexia","AIDS Wasting Syndrome","HIV Wasting Syndrome",[1807,1827],"Megestrol acetate oral suspension 40 mg\u002FmL",{"trials":1829,"activeCount":52},[],{"trials":1831,"activeCount":52},[],{"trials":1833,"activeCount":52},[],{"intervention":1827,"totalTrials":8,"cells":1835},{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1846,"PHASE4":1848,"NA":1850},{"trials":1837,"activeCount":52},[],{"trials":1839,"activeCount":52},[],{"trials":1841,"activeCount":52},[1842],{"nctId":1816,"briefTitle":1817,"status":60,"phases":1843,"primaryCompletion":1192,"completion":1192,"start":1819,"enrollment":1820,"conditions":1844,"interventions":1845},[43],[1425,1822,1823,1824,1825],[1807,1827],{"trials":1847,"activeCount":52},[],{"trials":1849,"activeCount":52},[],{"trials":1851,"activeCount":52},[],{"intervention":1853,"totalTrials":8,"cells":1854},"Megestrol acetate oral suspension 625 mg\u002F5 mL",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1869,"PHASE3":1871,"PHASE4":1873,"NA":1875},{"trials":1856,"activeCount":52},[],{"trials":1858,"activeCount":52},[1859],{"nctId":1860,"briefTitle":1861,"status":60,"phases":1862,"primaryCompletion":964,"completion":964,"start":1863,"enrollment":388,"conditions":1864,"interventions":1868},"NCT00638079","Evaluating the Effect of Food on Absorption of Megace ES",[42],"2006-06",[1865,1866,1867],"Pharmacokinetics","Bioavailability","Absorption",[1853,1853],{"trials":1870,"activeCount":52},[],{"trials":1872,"activeCount":52},[],{"trials":1874,"activeCount":52},[],{"trials":1876,"activeCount":52},[],{"intervention":1878,"totalTrials":8,"cells":1879},"Vasostrict Injectable Product",{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1895,"PHASE3":1897,"PHASE4":1899,"NA":1901},{"trials":1881,"activeCount":52},[],{"trials":1883,"activeCount":52},[1884],{"nctId":1885,"briefTitle":1886,"status":60,"phases":1887,"primaryCompletion":1888,"completion":1889,"start":1890,"enrollment":1891,"conditions":1892,"interventions":1894},"NCT04093050","Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers",[42],"2021-04-08","2021-04-11","2019-10-10",41,[1893],"Healthy Volunteer Safety Study",[1878],{"trials":1896,"activeCount":52},[],{"trials":1898,"activeCount":52},[],{"trials":1900,"activeCount":52},[],{"trials":1902,"activeCount":52},[],{"intervention":1904,"totalTrials":8,"cells":1905},"CCH",{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1917,"PHASE3":1919,"PHASE4":1921,"NA":1923},{"trials":1907,"activeCount":52},[],{"trials":1909,"activeCount":52},[1910],{"nctId":1911,"briefTitle":1912,"status":60,"phases":1913,"primaryCompletion":1914,"completion":1914,"start":222,"enrollment":1065,"conditions":1915,"interventions":1916},"NCT03675685","Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP",[42],"2018-11-01",[17],[1904],{"trials":1918,"activeCount":52},[],{"trials":1920,"activeCount":52},[],{"trials":1922,"activeCount":52},[],{"trials":1924,"activeCount":52},[],{"intervention":1926,"totalTrials":8,"cells":1927},"EN3342",{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1940,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1929,"activeCount":52},[],{"trials":1931,"activeCount":52},[1932],{"nctId":1933,"briefTitle":1934,"status":60,"phases":1935,"primaryCompletion":213,"completion":213,"start":1936,"enrollment":243,"conditions":1937,"interventions":1939},"NCT01774435","Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant",[42],"2012-10",[1938],"Schizophrenia",[1926],{"trials":1941,"activeCount":52},[],{"trials":1943,"activeCount":52},[],{"trials":1945,"activeCount":52},[],{"trials":1947,"activeCount":52},[],{"intervention":1949,"totalTrials":518,"cells":1950},"Previously Treated with EN3835",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1952,"activeCount":52},[],{"trials":1954,"activeCount":52},[],{"trials":1956,"activeCount":52},[],{"trials":1958,"activeCount":52},[],{"trials":1960,"activeCount":52},[],{"trials":1962,"activeCount":52},[1963,1971],{"nctId":1964,"briefTitle":1965,"status":60,"phases":1966,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":11,"conditions":1969,"interventions":1970},"NCT03893890","Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women",[],"2019-06-25","2019-03-28",[17],[1949],{"nctId":1972,"briefTitle":1973,"status":60,"phases":1974,"primaryCompletion":1975,"completion":1975,"start":1976,"enrollment":23,"conditions":1977,"interventions":1978},"NCT04381117","Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)",[],"2020-06-22","2020-05-06",[17],[1949],{"intervention":1980,"totalTrials":8,"cells":1981},"Subjects Previously Treated with AA4500",{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":1986,"PHASE3":1988,"PHASE4":1990,"NA":1992},{"trials":1983,"activeCount":52},[],{"trials":1985,"activeCount":52},[],{"trials":1987,"activeCount":52},[],{"trials":1989,"activeCount":52},[],{"trials":1991,"activeCount":52},[],{"trials":1993,"activeCount":52},[1994],{"nctId":1995,"briefTitle":1996,"status":60,"phases":1997,"primaryCompletion":1998,"completion":1998,"start":1999,"enrollment":2000,"conditions":2001,"interventions":2002},"NCT02298829","Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease",[],"2018-04-09","2014-11",184,[19],[1980],{"intervention":2004,"totalTrials":8,"cells":2005},"Xiapex",{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2012,"PHASE4":2014,"NA":2016},{"trials":2007,"activeCount":52},[],{"trials":2009,"activeCount":52},[],{"trials":2011,"activeCount":52},[],{"trials":2013,"activeCount":52},[],{"trials":2015,"activeCount":52},[],{"trials":2017,"activeCount":52},[2018],{"nctId":2019,"briefTitle":2020,"status":60,"phases":2021,"primaryCompletion":2022,"completion":2022,"start":290,"enrollment":2023,"conditions":2024,"interventions":2025},"NCT01444729","Post Approval Commitment Study",[],"2015-11",305,[22],[2004],{"intervention":2027,"totalTrials":8,"cells":2028},"Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies",{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2035,"PHASE4":2037,"NA":2039},{"trials":2030,"activeCount":52},[],{"trials":2032,"activeCount":52},[],{"trials":2034,"activeCount":52},[],{"trials":2036,"activeCount":52},[],{"trials":2038,"activeCount":52},[],{"trials":2040,"activeCount":52},[2041],{"nctId":2042,"briefTitle":2043,"status":70,"phases":2044,"primaryCompletion":2045,"completion":2045,"start":2046,"enrollment":925,"conditions":2047,"interventions":2048},"NCT04680156","Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)",[],"2022-09-12","2020-12-17",[28,31],[2027]]